-
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
Wednesday, June 26, 2024 - 6:58pm | 607Read More...A promising new startup, Ovax Inc., secured $10 million in funding to advance the development of a groundbreaking vaccine designed to prevent fentanyl-related deaths. The initiative focuses on commercializing academic research aimed at preventing the potent opioid from reaching the brain, reported...
-
Fintech Focus For June 11, 2021
Thursday, June 10, 2021 - 5:51pm | 2464Read More...Quote To Start The Day: "As my knowledge of things grew I felt more and more the delight of the world I was in.” Source: Helen Keller One Big Thing In Fintech: The Basel Committee on Banking Supervision on Thursday recommended the highest possible risk weighting — 1,250% —...
-
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Thursday, June 10, 2021 - 10:37am | 784Read More...Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co-founder and CEO, would step down. Benzinga spoke with Rahn on what the transition means for MindMed, the industry ...
-
MindMed Begins First-Ever Clinical Trial On MDMA, LSD Combinations
Wednesday, January 20, 2021 - 10:11am | 471Read More...Mind Medicine (MindMed) Inc (OTC: MMEDF), a medicine biotech company in psychedelics, on Wednesday announced its start of the first-ever clinical trial measuring and evaluating 3,4-methylenedioxymethamphetamine (MDMA) and lysergic acid diethylamide (LSD) combinations in the human body, at the...
-
How MindMed Uses Tech To Innovate, Deploy Psychedelic Mental Health Therapies
Wednesday, November 25, 2020 - 9:11am | 990Read More...In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...
-
MindMed Spearheads Phase 2 Trial Of LSD, Fending Off Mental Health Affliction, Impact Of COVID-19 Coronavirus
Tuesday, April 14, 2020 - 4:24pm | 568Read More...The COVID-19 coronavirus has prompted mass business closures, leading some economic forecasters to suggest 50 million jobs may be vulnerable to permanent layoffs, a scenario that may fuel the emergence of a mental health catastrophe. In a bid to address the arrival of a national health crisis, Mind...
